During the recent 2024 Straits Breast Cancer Forum and Fujian Medical Association Breast Disease Division Meeting, Oncology Frontier had the privilege of inviting Dr. Jian Huang from The Second Affiliated Hospital of Zhejiang University School of Medicine. He shared in-depth insights into advancements in neoadjuvant therapy for breast cancer downstaging and breast conservation, the significance and challenges of functional minimally invasive surgery, and his team's exploration and achievements in the field of basic and translational breast cancer research.

Focus on clinical priorities, summarize global advancements – the 2024 Lung Cancer Precision Therapy Academic Conference was held on December 15 in Shenzhen. Organized by the Southern Branch of the…

At the recent San Antonio Breast Cancer Symposium (SABCS), Professor Jiong Wu from Fudan University Shanghai Cancer Center presented the latest findings from a Phase I study on SIM0270 (Abstract Number: PS14-03). SIM0270, an innovative brain-penetrant oral selective estrogen receptor degrader (SERD), demonstrated significant clinical efficacy and excellent tolerability in patients with ER+/HER2- advanced breast cancer. Oncology Frontier invited the study’s leading investigator, Dr. Qingyuan Zhang from Harbin Medical University Cancer Hospital, to provide an in-depth interpretation of the results and share insights on future research directions.

With the rapid advancement of medical technology, the concept of precision medicine has been widely applied in the diagnosis and treatment of breast cancer. At the 47th San Antonio Breast Cancer Symposium (SABCS) in 2024, Chinese research gained significant attention, showcasing groundbreaking achievements in breast cancer treatment. During the "2024 Straits Breast Forum and the Annual Meeting of the Fujian Medical Association Breast Disease Branch," Oncology Frontier invited Dr. Benlong Yang from Fudan University Shanghai Cancer Center to share insights on the current treatment landscape, recent research progress, and future prospects in the management of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Traditionally, decisions regarding adjuvant chemotherapy after colorectal cancer surgery have been based on a patient's risk of recurrence, determined by TNM staging and histopathological features. However, emerging evidence suggests that these guidelines, in place since 2004, may not be the most effective approach and could be inadequate. In fact, surgery alone has already achieved high cure rates, preventing recurrence in 80% of stage II and 50% of stage III patients. Although adjuvant chemotherapy moderately improves disease-free survival (5–10% in stage II and 15–20% in stage III patients), many patients are exposed to unnecessary toxicity. Notably, even with adjuvant therapy, 15% of stage II and 30% of stage III patients still experience recurrence. This growing evidence highlights the relatively limited absolute benefit of adjuvant chemotherapy. Precisely predicting which patients will benefit from adjuvant therapy remains a significant challenge, underscoring the importance of developing more accurate biomarkers to guide treatment decisions.

Lateral lymph node (LLN) metastasis in locally advanced rectal cancer is associated with patient prognosis. However, the clinical significance of lateral lymph node dissection (LLND) has always been a matter of debate in the academic community. We have invited Dr. Petrv Tsarkov from Chechenov State Medical University in Moscow to share his insights and thoughts on the clinical controversies surrounding lymph node dissection in colorectal cancer.

The decision on whether high-risk MSI-H (microsatellite instability-high) stage II colorectal cancer patients should receive adjuvant therapy remains controversial. Dr. Ashwin Somasundaram, a medical professor at the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, shares his insights on this complex issue.